Company intelligence / Profile preview

Green3Bio

Ownership: Private
Development stage: Phase 1

Overview

GRN300, a first-in-class SIK2/3 inhibitor developed by Green3Bio, has entered Phase 1 clinical trials for ovarian cancer and TNBC. No published results yet; the program remains in early clinical development.

Therapeutic areas: Oncology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

GRN-300

Partnerships

Collaborates with parent company Greenfire Bio for asset acquisition and development

Beyond the preview

Go deeper on Green3Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Green3Bio.

Explore the full profile